Daiichi Sankyo is scrapping plans to build antibody-drug conjugate manufacturing capacity and recorded an “extraordinary loss” of 149.4 billion Japanese yen ($950 million) after overpromising

🗓️ FDA delays subcutaneous Leqembi decision: Originally slated for later this month, the decision date now falls on August 24, Biogen and Eisai said. The

Capricor has filed a lawsuit seeking to split from its commercial partner for Duchenne muscular dystrophy therapy, deramiocel, in the US.

RIO DE JANEIRO — Mazdak Abulnaga should be the poster child for the type of employee pharma companies want to hire this year. Abulnaga, a

Eisai and Biogen are facing a delay in the FDA review of injectable Leqembi for initial dosing in Alzheimer’s, viewed as a key growth driver.